Results 21 to 30 of about 22,974 (229)

A Case Report of a Dual Diagnosis Patient: Naltrexone for the Treatment of Severe Nitrous Oxide Use Disorder with Associated Neurological and Psychiatric Sequelae

Journal of Scientific Innovation in Medicine, 2023
Background: Nitrous oxide (N2O) is a non-regulated substance with increasing prevalence as a drug of abuse. N2O abuse is associated with both neurological and psychiatric sequelae, including psychotic symptoms.
Paige Juliet Staudenmaier, Veronica Kane, Amulya Iyer, Paul Campion   +3 more
doaj   +1 more source

Long-Acting Injectable naltrexone for the Management of patients with Opioid Dependence

Substance Abuse: Research and Treatment, 2011
Opioid dependence is a condition with serious clinical ramifications. Treatment has focused on detoxification, agonist therapy with methadone or buprenorphine, or remission maintenance with the opioid antagonist, naltrexone.
Kimberly L. Kjome, F. Gerard Moeller
doaj   +1 more source

Naltrexone engages a brain reward network in the presence of reward-predictive distractor stimuli in males

Addiction Neuroscience, 2023
The non-selective opioid receptor antagonist, naltrexone is one of the most prescribed medications for treating alcohol and opioid addiction. Despite decades of clinical use, the mechanism(s) by which naltrexone reduces addictive behavior remains unclear.
Cory N. Spencer, Amanda Elton, Samantha Dove, Monica L. Faulkner, Donita L. Robinson, Charlotte A. Boettiger   +5 more
doaj   +1 more source

Low-dose naltrexone-induced remission in Hailey–Hailey disease maintained in remission with topical combination of ketamine and diphenhydramine

Indian Dermatology Online Journal, 2019
Recent anecdotal evidence suggests that oral low-dose naltrexone (LDN) is effective for Hailey–Hailey disease (HHD) but suffers the limitation of immediate relapse following cessation of the medication.
Sidharth Sonthalia, Mahima Agrawal, Ankur Talwar, Mohamad Goldust   +3 more
doaj   +1 more source

Intranasal Low-Dose Naltrexone Against Opioid Side Effects: A Preclinical Study

Frontiers in Pharmacology, 2020
Opioids are broad spectrum analgesics that are an integral part of the therapeutic armamentarium to combat pain in the clinical practice. Unfortunately, together with analgesia, a number of adverse effects can occur such as nausea, vomiting, constipation,
Laura Micheli, Lorenzo Di Cesare Mannelli, Elena Lucarini, Carmen Parisio, Alessandra Toti, Bruno Fiorentino, Maria Adele Rigamonti, Laura Calosi, Carla Ghelardini   +8 more
doaj   +1 more source

Naltrexone therapeutic drug monitoring: A case series

Psychiatry and Clinical Psychopharmacology, 2021
Objective: Naltrexone is an opioid receptor antagonist.It is used in maintanence treatment of opiate dependence,alcohol dependence, prevention of relapse of alcohol dependence, treatment of cocaine dependence, nicotine dependence, eating disorders ...
Birim Sungu Danışmant, Nesrin Dilbaz, Esra Sağlam, Kaşif Nevzat Tarhan   +3 more
doaj  

Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors

Frontiers in Immunology, 2017
The opioid antagonist naltrexone hydrochloride has been suggested to be a potential therapy at low dosage for multiple inflammatory conditions and cancers.
Rachel Cant, Angus G. Dalgleish, Rachel L. Allen   +2 more
doaj   +1 more source

Quantitative Determination of Naltrexone Hydrochloride in a Nasal Spray by High-performance Liquid Chromatography

Разработка и регистрация лекарственных средств, 2020
Introduction. Naltrexone, an antagonist of µ-opioid receptors, is promising for the treatment of various autoimmune and oncological diseases when used in doses of 1.5–5 mg/day. To date, there are no medications that provide such dosages of naltrexone.Aim.
Yu. M. Domnina, V. V. Suslov, S. A. Kedik, E. V. Vorfolomeeva, A. V. Meleshko   +4 more
doaj   +1 more source

Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses.
Sooyoun Lee, Hyun Chul Kim, Young Ran Yoon, In‐Jin Jang, Sang‐Ku Yoo, Kyung‐Sang Yu   +5 more
wiley   +1 more source

Naltrexone Treatment for Methamphetamine Dependence – Service Evaluation Audit

BJPsych Open
Aims There is an emerging evidence base to support the benefit of naltrexone prescription in methamphetamine dependence. This audit assesses prescribing practice and benefit of naltrexone in a specialist NHS drug service based in West London.
Emma Stimson, Owen Bowden-Jones
doaj   +1 more source